Bruker Corporation

NasdaqGS:BRKR Stock Report

Market Cap: US$8.2b

Bruker Valuation

Is BRKR undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of BRKR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: BRKR ($53.43) is trading below our estimate of future cash flow value ($71.37)

Significantly Below Future Cash Flow Value: BRKR is trading below future cash flow value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for BRKR?

Key metric: As BRKR is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for BRKR. This is calculated by dividing BRKR's market cap by their current revenue.
What is BRKR's PS Ratio?
PS Ratio2.3x
SalesUS$3.50b
Market CapUS$8.16b

Price to Sales Ratio vs Peers

How does BRKR's PS Ratio compare to its peers?

The above table shows the PS ratio for BRKR vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average10x
RGEN Repligen
11.9x14.74%US$9.3b
QGEN Qiagen
4.2x6.05%US$8.7b
TXG 10x Genomics
14.5x8.33%US$8.9b
TECH Bio-Techne
9.3x8.02%US$11.3b
BRKR Bruker
2.3x4.72%US$8.2b

Price-To-Sales vs Peers: BRKR is good value based on its Price-To-Sales Ratio (2.3x) compared to the peer average (10x).

Historical Price to Sales Ratio

Historical Price to Sales Ratio compares a stock's price to its sales over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Sales Ratio vs Industry

How does BRKR's PS Ratio compare vs other companies in the US Life Sciences Industry?

11 CompaniesPrice / SalesEstimated GrowthMarket Cap
FTRE Fortrea Holdings
0.6x3.78%US$1.62b
QTRX Quanterix
0.8x9.90%US$118.23m
CIRC Circle8 Group
0.08xn/aUS$65.56m
HBIO Harvard Bioscience
0.4x4.99%US$36.51m
BRKR 2.3xIndustry Avg. 4.2xNo. of Companies11PS03.26.49.612.816+
11 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: BRKR is good value based on its Price-To-Sales Ratio (2.3x) compared to the US Life Sciences industry average (4.1x).

Price to Sales Ratio vs Fair Ratio

What is BRKR's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BRKR PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio2.3x
Fair PS Ratio4.1x

Price-To-Sales vs Fair Ratio: BRKR is good value based on its Price-To-Sales Ratio (2.3x) compared to the estimated Fair Price-To-Sales Ratio (4.1x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst BRKR forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$53.43
US$59.23
+10.86%
13.64%US$70.00US$40.00n/a13
Sep ’27US$56.03
US$58.75
+4.85%
14.00%US$70.00US$40.00n/a12
Aug ’27US$62.84
US$59.75
-4.92%
16.05%US$70.00US$40.00n/a12
Jul ’27US$60.64
US$53.83
-11.22%
18.42%US$69.00US$35.00n/a12
Jun ’27US$58.44
US$50.25
-14.01%
16.65%US$69.00US$35.00n/a12
May ’27US$36.79
US$46.79
+27.17%
14.16%US$60.00US$35.00n/a14
Apr ’27US$36.08
US$47.86
+32.64%
17.39%US$70.00US$35.00n/a14
Mar ’27US$40.11
US$48.43
+20.74%
18.00%US$70.00US$35.00n/a14
Feb ’27US$44.29
US$54.43
+22.89%
16.15%US$75.00US$40.00n/a14
Jan ’27US$47.11
US$51.79
+9.93%
19.44%US$75.00US$40.00n/a14
Dec ’26US$47.86
US$48.83
+2.03%
20.04%US$75.00US$40.00n/a12
Nov ’26US$38.94
US$46.45
+19.30%
18.41%US$65.00US$38.00n/a11
Oct ’26US$34.72
US$46.73
+34.58%
17.95%US$65.00US$38.00n/a11
Sep ’26US$33.98
US$46.73
+37.51%
17.95%US$65.00US$38.00US$56.0311
Aug ’26US$37.99
US$54.82
+44.30%
19.11%US$72.00US$40.00US$62.8411
Jul ’26US$41.90
US$53.95
+28.75%
19.34%US$72.00US$40.00US$60.6412
Jun ’26US$36.70
US$55.13
+50.22%
18.67%US$72.00US$40.00US$58.4413
May ’26US$39.35
US$60.13
+52.81%
16.55%US$80.00US$45.00US$36.7913
Apr ’26US$40.38
US$68.42
+69.43%
12.99%US$80.00US$55.00US$36.0813
Mar ’26US$47.22
US$68.42
+44.89%
12.99%US$80.00US$55.00US$40.1113
Feb ’26US$58.15
US$73.49
+26.39%
9.28%US$85.00US$60.00US$44.2913
Jan ’26US$58.62
US$73.80
+25.90%
9.50%US$85.00US$60.00US$47.1113
Dec ’25US$57.95
US$74.74
+28.97%
9.41%US$85.00US$60.00US$47.8611
Nov ’25US$59.29
US$78.28
+32.03%
10.33%US$90.00US$60.00US$38.9411
Oct ’25US$66.76
US$79.51
+19.10%
10.56%US$90.00US$60.00US$34.7210
Sep ’25US$67.19
US$79.74
+18.68%
10.08%US$90.00US$60.00US$33.9811
US$59.23
Fair Value
9.8% undervalued intrinsic discount
13
Number of Analysts

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/11 23:08
End of Day Share Price 2026/09/11 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Bruker Corporation is covered by 33 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Luke SergottBarclays
Lu LiBofA Global Research
Michael RyskinBofA Global Research